Cheng-I Wang

This inventor holds 30 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 8 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Agency for Science, Technology and Research, Chugai Seiyaku Kabushiki Kaisha, National University of Singapore. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Cheng-I Wang. Retrieved from https://idiyas.com/inventor/cheng-i-wang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30 (Patent Applications = 9)

% Patents Active = 86.7

CIPO Patents = 1 (Patent Applications = 34)

EPO Patents = 8 (Patent Applications = 26)

Average Co-Inventor Count = 4.4

ph-index = 5

Forward Citations = 106(Granted Patents)

Company Filing History:

29 out of 1,561

Agency for Science, Technology and Research

patents

2 out of 987

Chugai Seiyaku Kabushiki Kaisha

patents

1 out of 854

National University of Singapore

patents

where one patent can have more than one assignee

Years Active: 2016-2026

Loading Chart...

Areas of Expertise:

Anti-PD-L1

Anti-PD-1

Monoclonal Antibodies

IL-1β Neutralization

Glypican-3

Anti-HER2

Anti-CTLA-4

Anti-TIM-3

Dengue Virus

Zika Virus

Chikungunya Virus

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12662526 - ANTI-DENGUE VIRUS ANTIBODIES HAVING CROSS-REACTIVITY TO ZIKA VIRUS AND METHODS OF USE (2026-06-23),

2. 12655227 - MODIFIED FC REGION (2026-06-16),

3. 12472252 - ANTI-PD-L1 ANTIBODIES (2025-11-18),

4. 12404341 - Glypican-3 (GPC-3) antibodies (2025-09-02),

5. 11945877 - Anti-HER2 antibodies (2024-04-02),

6. 11912761 - IL-1β neutralizing human monoclonal antibodies (2024-02-27),

7. 11891432 - Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use (2024-02-06),

8. 11780913 - IL-1β neutralizing human monoclonal antibodies (2023-10-10),

9. 11702471 - IL-1β neutralizing human monoclonal antibodies (2023-07-18),

10. 11534489 - Anti-PD-L1 antibodies (2022-12-27),

11. 11267887 - Anti-CTLA-4 antibodies (2022-03-08),

12. 11142574 - Anti-TIM-3 antibodies (2021-10-12),

13. 11072659 - Anti-PD-1 antibodies (2021-07-27),

14. 10919962 - Method of reducing tumor growth with IL-1beta neutralizing human monoclonal antibodies (2021-02-16),

15. 10696747 - IL2R common gamma chain antibodies (2020-06-30),

Title: The Innovative Journey of Cheng-I Wang

Introduction: Cheng-I Wang is a pioneering inventor hailing from Singapore, SG. His groundbreaking work in the field of technology has left a lasting impact on various industries worldwide.

Latest Patents: Cheng-I Wang holds several patents in the areas of artificial intelligence, robotics, and renewable energy. His most recent patents focus on sustainable solutions for urban development and smart city initiatives.

Career Highlights: With a career spanning over two decades, Cheng-I Wang has worked with leading tech companies and research institutions to bring his innovative ideas to life. He has been recognized for his contributions to the advancement of technology through numerous awards and accolades.

Collaborations: Throughout his career, Cheng-I Wang has collaborated with top engineers, scientists, and designers to push the boundaries of innovation. His ability to work across disciplines has led to the development of cutting-edge technologies that have revolutionized the way we live and work.

Conclusion: Cheng-I Wang's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and entrepreneurs. His impact on the world of technology is truly remarkable, and his legacy will undoubtedly shape the future of innovation for years to come.

Profile summary based on public USPTO records.